Edaravone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12243 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 25 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | heparin cofactor 2 deficiency | KG + DL |
| 2 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 3 | bilateral parasagittal parieto-occipital polymicrogyria | KG + DL |
| 4 | antithrombin deficiency type 2 | KG + DL |
| 5 | axial spondylometaphyseal dysplasia | KG + DL |
| 6 | amyotrophic lateral sclerosis, susceptibility to | KG + DL |
| 7 | amyotrohpic lateral sclerosis type 22 | KG + DL |
| 8 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | KG + DL |
| 9 | Mills syndrome | KG + DL |
| 10 | lower motor neuron syndrome with late-adult onset | KG + DL |
| 11 | lethal arthrogryposis-anterior horn cell disease syndrome | KG + DL |
| 12 | monomelic amyotrophy | KG + DL |
| 13 | autosomal dominant mitochondrial myopathy with exercise intolerance | KG + DL |
| 14 | ABri amyloidosis | KG + DL |
| 15 | thrombophilia | KG + DL |
| 16 | homozygous familial hypercholesterolemia | KG + DL |
| 17 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 18 | rheumatoid arthritis | KG + DL |
| 19 | brachydactyly-syndactyly syndrome | KG + DL |
| 20 | sagittal sinus thrombosis | KG + DL |
| 21 | brain stem infarction | KG + DL |
| 22 | myocardial infarction (disease) | KG + DL |
| 23 | pyruvate kinase deficiency of red cells | KG + DL |
| 24 | cerebral artery occlusion | KG + DL |
| 25 | pyropoikilocytosis, hereditary | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.